dc.contributor.author | Cayssials, Emilie | |
dc.contributor.author | Turhan, Ali G. | |
dc.contributor.author | Sorel, Nathalie | |
dc.contributor.author | Chomel, Jean-Claude | |
dc.contributor.author | Bennaceur-Griscelli, Annelise | |
dc.contributor.author | Imeri, Jusuf | |
dc.contributor.author | Desterke, Christophe | |
dc.contributor.author | Marcoux, Paul | |
dc.contributor.author | Telliam, Gladys | |
dc.contributor.author | Sanekli, Safa | |
dc.contributor.author | Barreau, Sylvain | |
dc.contributor.author | ERBİLGİN, Yücel | |
dc.contributor.author | Latsis, Theodoros | |
dc.contributor.author | Hugues, Patricia | |
dc.date.accessioned | 2023-05-29T10:47:26Z | |
dc.date.available | 2023-05-29T10:47:26Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Imeri J., Desterke C., Marcoux P., Telliam G., Sanekli S., Barreau S., ERBİLGİN Y., Latsis T., Hugues P., Sorel N., et al., "Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs)", Cells, cilt.12, sa.4, 2023 | |
dc.identifier.issn | 2073-4409 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_001bedcd-9599-43aa-ae83-778be134304d | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/188581 | |
dc.identifier.uri | https://doi.org/10.3390/cells12040598 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/001bedcd-9599-43aa-ae83-778be134304d/file | |
dc.description.abstract | Purpose: To model CML progression in vitro and generate a blast crisis (BC-CML) model in vitro in order to identify new targets. Methods: Three different CML-derived iPSC lines were mutagenized with the alkylating agent ENU on a daily basis for 60 days. Cells were analyzed at D12 of hematopoietic differentiation for their phenotype, clonogenicity, and transcriptomic profile. Single-cell RNA-Seq analysis has been performed at three different time points during hematopoietic differentiation in ENU-treated and untreated cells. Results: One of the CML-iPSCs, compared to its non-mutagenized counterpart, generated myeloid blasts after hematopoietic differentiation, exhibiting monoblastic patterns and expression of cMPO, CD45, CD34, CD33, and CD13. Single-cell transcriptomics revealed a delay of differentiation in the mutated condition as compared to the control with increased levels of MSX1 (mesodermal marker) and a decrease in CD45 and CD41. Bulk transcriptomics analyzed along with the GSE4170 GEO dataset reveal a significant overlap between ENU-treated cells and primary BC cells. Among overexpressed genes, CD25 was identified, and its relevance was confirmed in a cohort of CML patients. Conclusions: iPSCs are a valuable tool to model CML progression and to identify new targets. Here, we show the relevance of CD25 identified in the iPSC model as a marker of CML progression. | |
dc.language.iso | eng | |
dc.subject | Genel Biyokimya, Genetik ve Moleküler Biyoloji | |
dc.subject | Temel Bilimler | |
dc.subject | Sitogenetik | |
dc.subject | Yaşam Bilimleri | |
dc.subject | BİYOKİMYA VE MOLEKÜLER BİYOLOJİ | |
dc.subject | Moleküler Biyoloji ve Genetik | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.title | Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs) | |
dc.type | Makale | |
dc.relation.journal | Cells | |
dc.contributor.department | Université Paris-Saclay , , | |
dc.identifier.volume | 12 | |
dc.identifier.issue | 4 | |
dc.contributor.firstauthorID | 4255110 | |